• 아이콘 LOCALLY SOURCED

    To find and license promising
    development candidates from
    domestic biotech/pharma
    companies and universities

  • 아이콘 REGIONALLY FINANCED

    To establish sources of financing
    from regional investment
    communities

  • 아이콘 GLOBALLY DEVELOPED

    To develop assets up to human
    PoC(Proof of Concept) globally

아이콘

Pipeline

We have initially focused on small molecular entities (SME) for the treatment of inflammatory and fibrotic diseases and are gradually expanding our interests to the immuno-oncology field with advanced modalities.

이미지
아이콘

News

Bridge Biotherapeutics Presented Preclinical and Phase I Study Results for BBT-401 at the Crohn's & Colitis Congress

Bridge Biotherapeutics Inc., a clinical stage biotech company headquartered in Seongnam, South Korea, announced that the company presented the preclinical and the Phase I study results for BBT-401, a drug candidate for Ulcerative Colitis (UC) treatment, at the poster session of the Crohn's & Colitis Congress held in Las Vegas, NV from February 7th to 9th. The congress, which is based on a par...

Read More

  • LEARN MORE ABOUT US
    페이스북 트위터 링크드인
  • CONTACT INFORMATION

    HQ: Suite 903-2, Bldg B, Innovalley, 253 Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, 13486 Republic of Korea
    US Office: Bridge Biotherapeutics, Inc. in JLABS@TMC, 2450 Holcombe Blvd. Houston, TX 77021, USA

    Director, Jong-jin Lim (jong-jin.lim@bridgebiorx.com)
    Manager, Joengbin Ahn (Joengbin.ahn@bridgebiorx.com)